Diet, Physical Activity and Body Composition Changes During R-CHOP
NCT04293900 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2020-10-06
Summary
In this pilot study, observational data will be collected to describe the usual trajectory of changes in dietary intake, ability to be physically active, body composition, environmental exposures, and the gut microbiome over the course of R-CHOP treatment for non-Hodgkin lymphoma (NHL).
Conditions
Interventions
- OTHER
-
24-hour dietary recall
Dietary intake assessment conducted by a Registered Dietitian Nutritionist. This assessment will occur prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
- OTHER
-
Hand grip strength
Measurement of grip strength using a hand dynamometer. This will test occur prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
- OTHER
-
International Physical Activity Questionnaire
Survey about physical activity over the previous 7 days. This survey will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
- OTHER
-
Patient-reported outcomes survey
Survey about symptoms and side effects experienced during cancer treatment. This will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
- OTHER
-
Pittsburgh Sleep Quality Index
Survey about sleep habits and quality over the past month. This will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
- OTHER
-
Functional Assessment of Cancer Treatment - Lymphoma
Survey about quality of life for people with a diagnosis of lymphoma. This will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
- OTHER
-
urine sample (optional)
Collect three urine samples either in the clinic or at home. This specimen collection will occur prior to starting R-CHOP chemotherapy, after the third round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
- OTHER
-
fecal sample (optional)
Collect a fecal sample either in the clinic or at home. This sample collection will occur prior to starting R-CHOP chemotherapy, after the third round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
Sponsors & Collaborators
-
George Washington University
lead OTHER
Principal Investigators
-
Kim Robien, PhD, RD · Milken Institute School of Public Health, George Washington University
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-01-31
- Primary Completion
- 2023-12-31
- Completion
- 2023-12-31
Countries
- United States
Study Locations
More Related Trials
-
Split-Dose R-CHOP for Older Adults With DLBCL
NCT03943901 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma
NCT00003150 ·Status: COMPLETED ·Phase: PHASE3
-
Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL
NCT00209209 ·Status: UNKNOWN ·Phase: PHASE3
-
Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma
NCT00129090 ·Status: COMPLETED ·Phase: PHASE3
-
Kinetics of Circulating Tumor DNA in Lymphoma Treated by Immuno-chemotherapy
NCT06141772 ·Status: COMPLETED ·Phase: NA
-
Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL
NCT01279902 ·Status: UNKNOWN ·Phase: PHASE2
-
CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma
NCT00574730 ·Status: COMPLETED ·Phase: NA
-
A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma
NCT01569750 ·Status: COMPLETED ·Phase: PHASE1
-
Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma
NCT00052936 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
NCT03003520 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma
NCT01539174 ·Status: WITHDRAWN ·Phase: PHASE2
-
Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL
NCT00209222 ·Status: UNKNOWN ·Phase: PHASE3
-
Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma
NCT05097443 ·Status: UNKNOWN ·Phase: PHASE3
-
IMPACT Non Hodgkins Lymphoma (NHL) Study
NCT00903812 ·Status: COMPLETED
-
Genotype-guided Treatment in DLBCL
NCT05351346 ·Status: RECRUITING ·Phase: PHASE3
-
R-CHOP + GM-CSF for Previously Untreated LCL in Elderly
NCT00582725 ·Status: COMPLETED ·Phase: PHASE2
-
This Trial is a Prospective Observational Study of Newly Diagnosed Diffuse Large B Cell Primary Breast Lymphomas
NCT01279772 ·Status: TERMINATED
-
Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma
NCT02285062 ·Status: COMPLETED ·Phase: PHASE3
-
Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma
NCT00004039 ·Status: WITHDRAWN ·Phase: PHASE2
-
Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment
NCT00324467 ·Status: UNKNOWN ·Phase: PHASE2
-
Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)
NCT02531308 ·Status: TERMINATED ·Phase: PHASE2
-
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
NCT04824092 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma
NCT00121199 ·Status: COMPLETED ·Phase: PHASE2
-
Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma
NCT00575406 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma
NCT00193479 ·Status: COMPLETED ·Phase: PHASE2